Literature DB >> 6207950

Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.

R L Momparler, J Samson, L F Momparler, G E Rivard.   

Abstract

The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to the cytotoxic effects of 5-AZA-CdR than cells in the plateau phase of growth. These results indicate that 5-AZA-CdR produces a preferential kill of cells in the S phase of the cell cycle. 5-AZA-CdR did not block the cell cycle progression of cells into S phase. The survival curve of EMT6 cells exposed to 5-AZA-CdR suggests that the cytotoxic action of this analogue is not self-limiting. The mutagenic activity of 5-AZA-CdR was investigated using induction of 6-thioguanine resistance in Chinese hamster ovary cells. 5-AZA-CdR was not a detectable mutagen in this assay system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207950     DOI: 10.1007/bf00269027

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line.

Authors:  P R Twentyman; J V Watson; N M Bleehen; P M Rowles
Journal:  Cell Tissue Kinet       Date:  1975-01

2.  Growth and nucleic acid synthesis in synchronously dividing populations of HeLa cells.

Authors:  T TERASIMA; L J TOLMACH
Journal:  Exp Cell Res       Date:  1963-04       Impact factor: 3.905

3.  Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse.

Authors:  R A Tobey
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

4.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.

Authors:  S C Rockwell; R F Kallman; L F Fajardo
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

5.  Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.

Authors:  F Sorm; J Veselý
Journal:  Neoplasma       Date:  1968       Impact factor: 2.575

6.  5-azacytidine in childhood leukemia.

Authors:  O Hrodek; J Veselý
Journal:  Neoplasma       Date:  1971       Impact factor: 2.575

7.  Phase specificity of 5-azacytidine against mammalian cells in tissue culture.

Authors:  L H Li; E J Olin; T J Fraser; B K Bhuyan
Journal:  Cancer Res       Date:  1970-11       Impact factor: 12.701

8.  Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase.

Authors:  R L Momparler; D Derse
Journal:  Biochem Pharmacol       Date:  1979-04-15       Impact factor: 5.858

9.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

10.  Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice.

Authors:  J Veselý; A Cihák
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

View more
  17 in total

1.  Exploiting drug repositioning for discovery of a novel HIV combination therapy.

Authors:  Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

Authors:  B J Braakhuis; G A van Dongen; M van Walsum; A Leyva; G B Snow
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

Review 3.  DNA methylation as a target for drug design.

Authors:  C M Bender; J M Zingg; P A Jones
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

4.  Investigation of Decitabine Effects on HDAC3 and HDAC7 mRNA Expression in NALM-6 and HL-60 Cancer Cell Lines.

Authors:  Sina Dalvand; Amin Namdari; Farzad Sepahvand; Mohammad Hassan Meshkibaf; GholamReza Ahmadpour
Journal:  Rep Biochem Mol Biol       Date:  2021-10

5.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

6.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

7.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

8.  Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines.

Authors:  Sabine Hagemann; Oliver Heil; Frank Lyko; Bodo Brueckner
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

9.  Carcinogenicity and haemoglobin synthesis induction by cytidine analogues.

Authors:  B I Carr; S Rahbar; Y Asmeron; A Riggs; C D Winberg
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

10.  Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Authors:  Maryse Lemaire; Guy G Chabot; Noël Jm Raynal; Louise F Momparler; Annie Hurtubise; Mark L Bernstein; Richard L Momparler
Journal:  BMC Cancer       Date:  2008-05-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.